Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- New Pfizer to Become World's Premier Biopharma Company: CEO Jeff Kindler
February 9, 2009
- PICCs Cut Treatment Costs by Reducing Incidence of Complications
February 9, 2009
- Acquisition of Wyeth Does Not Solve Problems: Datamonitor Report
February 9, 2009
- MEDICAL DEVICE NEWS IN BRIEF
February 9, 2009
- Astellas Interested in CV Therapeutics' Product Lineup
February 9, 2009
- Mochida to Develop OTC Versions of Epadel
February 9, 2009
- aRigen Licenses New Anti-Peptic Ulcer Agent to Taiho
February 9, 2009
- LDP Diet Members to Discuss Online Sale of OTC Drugs
February 9, 2009
- Novartis to Comarket Lucentis with Alcon Japan
February 9, 2009
- Updated GL for Colon Cancer to Recommend Bevacizumab, Cetuximab
February 9, 2009
- GSK's 1,200 MRs Start Detailing Adoair for COPD
February 9, 2009
- SELF-MEDICATION NEWS IN BRIEF
February 9, 2009
- ARB + Diuretic Combinations from Takeda, Novartis Approved at the Same Time
February 2, 2009
- JGA to Make Proposals to Improve Environment for Use of Generics
February 2, 2009
- NEW PRODUCTS
February 2, 2009
- Industry Should Make Concerted Efforts to Make Generics More Reliable: Mr Kinoshita
February 2, 2009
- Pfizer to Acquire Wyeth
February 2, 2009
- Oncolys, Sysmex to Jointly Develop Diagnostic Agents for Cancer
February 2, 2009
- Industry Concerned about Obama Administration's Intervention in Drug Pricing
February 2, 2009
- FUJIFILM to Market Given Imaging's PillCam SB Endoscope
February 2, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…